Deutsche Bank set a $68.00 target price on Teva Pharmaceutical Industries (NASDAQ:TEVA) in a research note released on Monday morning. The firm currently has a a buy rating on the stock.
Deutsche Bank has also taken action a number of other healthcare stocks recently. The firm reiterated its buy rating on shares of Embraer SA. They have a $40.00 price target on that stock. Also, Deutsche Bank reiterated its buy rating on shares of The Blackstone Group L.P.. They have a $44.00 price target on that stock. Finally, Deutsche Bank reiterated its buy rating on shares of Vodafone Group Plc.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Several other analysts have also recently commented on the stock. Analysts at Standpoint Research reiterated a buy rating and set a $78.00 price target (up previously from $66.00) on shares of Teva Pharmaceutical Industries in a research note on Tuesday, March 24th. Analysts at JPMorgan Chase & Co. raised their price target on shares of Teva Pharmaceutical Industries from $60.00 to $65.00 and gave the company a neutral rating in a research note on Tuesday, March 17th.
Analysts at Leerink Swann raised their price target on shares of Teva Pharmaceutical Industries from $67.00 to $69.00 and gave the company an outperform rating in a research note on Tuesday, March 10th. Finally, analysts at Oppenheimer reiterated a hold rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, February 11th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $64.11.
Shares of Teva Pharmaceutical Industries traded up 0.87% on Monday, hitting $62.52. The stock had a trading volume of 8, 496, 267 shares. Teva Pharmaceutical Industries has a 52-week low of $47.36 and a 52-week high of $64.08. The stock has a 50-day moving average of $58. and a 200-day moving average of $56.. The company has a market cap of $53.26 billion and a price-to-earnings ratio of 17.56.
Teva Pharmaceutical Industries (NASDAQ:TEVA) last released its earnings data on Thursday, February 5th. The company reported $1.31 earnings per share for the quarter, meeting the analysts’ consensus estimate of $1.31. The company had revenue of $5.17 billion for the quarter, compared to the consensus estimate of $5.17 billion. During the same quarter last year, the company posted $1.42 earnings per share. Teva Pharmaceutical Industries’s revenue was down 4.8% compared to the same quarter last year. On average, analysts predict that Teva Pharmaceutical Industries will post $5.14 earnings per share for the current fiscal year.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect.
